Actively Recruiting
Phase II Study of TURP Surgery Combined with Standard Systemic Therapy for Treating Metastatic Prostate Cancer in Men Aged 18 to 80
Led by Fudan University · Updated on 2024-10-23
200
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combination treatment for patients with newly diagnosed metastatic prostate cancer. This Phase II, open-label clinical study aims to assess the safety and effectiveness of combining transurethral resection of the prostate TURP with standard systemic therapies, including androgen deprivation therapy ADT and second-generation anti-androgen drugs like abiraterone or enzalutamide. The study focuses on improving outcomes such as radiographic progression-free survival and quality of life. Participants will first undergo TURP, a surgical procedure designed to relieve urinary blockage and reduce tumor size. After surgery, they will receive standard systemic therapy involving ADT using either LHRH agonists or antagonists, combined with anti-androgen medications. The study is single-arm and prospective, meaning all participants receive this combined treatment, with follow-up planned over two years to evaluate treatment impact and safety. During the study, participants will have regular monitoring including imaging scans to measure disease progression, blood tests to assess biochemical markers like PSA response at 3 and 6 months, and quality of life assessments at multiple time points. Researchers will track urinary symptom relief, overall survival, and biochemical progression-free survival, ensuring comprehensive evaluation of treatment effects and safety throughout the study period.
CONDITIONS
Brief Title
Combination of TURP and Standard Systemic Therapy for MPCa
Research Team
D
Dingwei Ye, MD.
X
Xiaojian Qin, MD.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here